The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms

This publication has 15 references indexed in Scilit:

• Aggressive surgery for metastatic liver neuroendocrine tumors
  Surgery, 2003
• A 5‐decade analysis of 13,715 carcinoid tumors
  Cancer, 2003
• Evaluation of 111In-pentetreotide, 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease
  Nuclear Medicine Communications, 2002
• 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome
  European Journal of Surgical Oncology, 2001
• Hepatic neuroendocrine metastases: does intervention alter outcomes?1
  Journal of the American College of Surgeons, 2000
• Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours
  Nuclear Medicine Communications, 2000
• Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG)
  European Journal of Gastroenterology & Hepatology, 1999
• Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
  Seminars in Nuclear Medicine, 1995
• Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine
  Nuclear Medicine Communications, 1993
• Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours
  European Journal Of Cancer, 1992